The Court of Federal Claims recently denied the United States’ motion to dismiss a patent infringement suit related to production of a COVID-19 vaccine. The court held that it had jurisdiction because the plaintiff filed its claim there before it filed a parallel suit in a district court and because it adequately pleaded the government’s involvement.
The patent at issue claims a fluorescent protein that can be used in vaccine development. Pursuant to a U.S. government contract awarded through Op...
Continue Reading
Sign up for FREE to read the full article and access 151K+ alternative investment headlines.
Alternative Investment News